News

Synlogic announced that it has dosed the first subject in its Phase 1/2a clinical trial of SYNB1618. SYNB1618 is a Synthetic Biotic medicine being developed for the treatment of…
Read More...

Astellas Pharma and Kite, a Gilead Company announced that an agreement has been completed for the transfer of certain Agensys research facilities in Santa Monica, California, USA, to…
Read More...

ProBioGen AG announced that it has signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, Inc., a privately held immunology company,…
Read More...

Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the…
Read More...

During the past several years, many strains of bacteria have become resistant to existing antibiotics, and very few new drugs have been added to the antibiotic arsenal. To help…
Read More...

GE Healthcare is launching a ready-to-run factory-in-a-box to speed up the production of viral vector based therapeutics, including viral vector based vaccines, oncolytic viruses and…
Read More...

Merck announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. The…
Read More...

SAMDI Tech, Inc. has partnered with Enamine to expand the number of molecules in their small molecule compound libraries. Through the partnership, SAMDI Tech will be able to offer its…
Read More...

Shire plc announces that it has entered into a definitive agreement with Servier S.A.S. to sell its Oncology business for $2.4 billion. Shire's Oncology business includes in-market…
Read More...

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced that it has signed a collaborative agreement with Plexxikon Inc., the…
Read More...

Cardurion Pharmaceuticals announced it has entered an exclusive licensing agreement with Astellas to develop and commercialize CRD-733, a PDE-9 inhibitor with the potential to improve…
Read More...

Sobi has received approval from Health Canada for a reduced dosing frequency for Orfadin (nitisinone). Orfadin is approved in combination with dietary restriction of tyrosine and…
Read More...

Boehringer Ingelheim and Eli Lilly and Company announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney…
Read More...

Almac Group announced that it has expanded its US commercial packaging capabilities at its Audubon, PA facility. Addressing increased client demand of developing and bringing more…
Read More...

BioAscent Discovery Limited has announced the launch of a comprehensive suite of integrated drug discovery services with immediate effect. Dr Phil Jones will be joining as Chief…
Read More...

MilliporeSigma announced a partnership with Oxford University's Jenner Institute to develop more robust and scalable vaccine manufacturing processes. This partnership, as well as plans…
Read More...

GSK and Orchard Therapeutics announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard,…
Read More...

Sanofi is investing €350 million (CAD $500 million) for the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto,…
Read More...

“This milestone showcases the productivity of our collaboration with LEO Pharma, marking the final step before ARGX-112 may enter clinical development. It triggers the third of three…
Read More...

Ionis Pharmaceuticals announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca following advancement of the drug into development. IONIS-AZ6-2.5-LRx is designed to…
Read More...